Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bariatric Surgery in Children. (BASIC)

25. august 2021 oppdatert av: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Limburg
      • Maastricht, Limburg, Nederland, 6202ZA
        • Maastricht University Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

14 år til 16 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Kontrollgruppe
Control group will receive standard therapy consisting of combined lifestyle interventions.
Eksperimentell: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Weight
Tidsramme: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Tidsramme: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Tidsramme: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Tidsramme: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Body composition
Tidsramme: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Tidsramme: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Tidsramme: 6 months
6 months
Inflammatory status
Tidsramme: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Tidsramme: 6 months
6 months
Non-alcoholic fatty liver disease
Tidsramme: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Tidsramme: 6 months
6 months
Behaviour changes
Tidsramme: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Tidsramme: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Tidsramme: 6 months
6 months
Brain development
Tidsramme: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Tidsramme: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Tidsramme: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Tidsramme: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Tidsramme: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Tidsramme: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Tidsramme: 12 months
12 months
Metabolic and endocrine changes
Tidsramme: 24 months
24 months
Metabolic and endocrine changes
Tidsramme: 36 months
36 months
Inflammatory status
Tidsramme: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Tidsramme: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Tidsramme: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Tidsramme: 12 months
12 months
Cardiovascular abnormalities
Tidsramme: 24 months
24 months
Cardiovascular abnormalities
Tidsramme: 36 months
36 months
Non-alcoholic fatty liver disease
Tidsramme: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Tidsramme: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Tidsramme: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Tidsramme: 12 months
12 months
Quality of life changes
Tidsramme: 24 months
24 months
Quality of life changes
Tidsramme: 36 months
36 months
Effects on sleep architecture
Tidsramme: 12 months
12 months
Effects on sleep architecture
Tidsramme: 24 months
24 months
Effects on sleep architecture
Tidsramme: 36 months
36 months
Behaviour changes
Tidsramme: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Tidsramme: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Tidsramme: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Tidsramme: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Tidsramme: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Tidsramme: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Tidsramme: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Tidsramme: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Tidsramme: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Tidsramme: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Tidsramme: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Tidsramme: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Tidsramme: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Tidsramme: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: LWE van Heurn, Professor, Maastricht University Medical Center
  • Hovedetterforsker: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Hovedetterforsker: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2011

Primær fullføring (Forventet)

1. desember 2022

Studiet fullført (Forventet)

1. desember 2022

Datoer for studieregistrering

Først innsendt

22. juli 2010

Først innsendt som oppfylte QC-kriteriene

29. juli 2010

Først lagt ut (Anslag)

30. juli 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. august 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. august 2021

Sist bekreftet

1. august 2021

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NL26279.068.09

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere